- Home
- EPM vs YARW Comparison
EPM vs YARW Comparison
Compare EPM & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EPM | YARW |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.2M | 114.6M |
| IPO Year | 1996 | 2017 |
Fundamental Metrics
Financial Performance| Metric | EPM | YARW |
|---|---|---|
| Price | $3.74 | $42.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.83 | N/A |
| AVG Volume (30 Days) | ★ 273.7K | 17.5K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | ★ 10.08% | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,229,621.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.19 | $31.55 |
| 52 Week High | $5.70 | $44.28 |
Technical Indicators
Market Signals| Indicator | EPM | YARW |
|---|---|---|
| Relative Strength Index (RSI) | 49.72 | 77.60 |
| Support Level | $3.48 | N/A |
| Resistance Level | $4.84 | $44.28 |
| Average True Range (ATR) | 0.11 | 3.41 |
| MACD | 0.02 | 0.80 |
| Stochastic Oscillator | 53.33 | 82.10 |
Price Performance
Historical ComparisonAbout EPM Evolution Petroleum Corporation Inc.
Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.
About YARW Yarrow Bioscience Inc. Common Stock
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.